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Abstract
Chronic liver diseases (CLDs) are increasing in prevalence and their end-stage complications, namely, cirrhosis, liver failure and
hepatocellular carcinoma represent major global challenges. The most common initiators of progressive CLD are viral hepatitis
and long-term alcohol abuse as well as steatosis and steatohepatitis. Irrespective of the underlying aetiology, a common feature
of CLD is the formation of hepatic ductular reactions, involving the proliferation of liver progenitor cells (LPCs) and their signalling to fibrosis-driving hepatic stellate cells. The Wnt/β-catenin pathway has been found to regulate development, stemness
and differentiation, and alterations in its activity have been associated with tumour development. Recent data highlight the role
of Wnt/β-catenin signalling in hepatic metabolism, steatosis and cancer, and suggest targeting of this pathway as a promising
molecular strategy to potentially inhibit CLD progression and hepatocarcinogenesis.
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Introduction
Chronic liver disease (CLD) has become one of the most
common causes of death globally with an estimated 1.03
million deaths per year, as reported in 2017. Excessive alcohol consumption, viral hepatitis and hepatic steatosis are
the most prevalent risk factors for the initiation and progression of CLD (1). A UK report stated that standardised CLD

mortality rates have increased by 400% since 1970, reflecting its growing burden and major challenge for global health
(2). End-stage complications of CLD include cirrhosis, liver
failure and malignancies, with hepatocellular carcinoma constituting 85–90% of all liver cancers (3). Current therapy options for hepatocellular carcinoma include surgical resection,
radiofrequency ablation, transarterial chemoembolisation
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and orthotopic liver transplantation. The multikinase inhibitors sorafenib and regorafenib are the only systemic
treatments with proven survival benefits and they prolong
the life expectancy of patients by 2 to 3 months (4). Immune-based approaches, including targeting of the immune checkpoint inhibitors programmed cell death (PD-1),
programmed cell death ligand 1 (PD-L1) or cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4), represent

novel, promising therapeutic strategies to prevent or treat
hepatocellular carcinoma (5).

Chronic Liver Disease and the Ductular Reaction
CLD induces molecular and cellular processes, which are initially reparative but become detrimental in the prolonged setting. Damaged liver epithelial cells release pro-inflammatory
signalling molecules, which recruit immune cells to the site
of injury, induce collagen deposition or fibrosis and activate
liver progenitor cells (LPCs) as part of the so-called ‘ductular

reactions’ to restore lost liver tissue. The term ductular reaction describes the diverse histological phenomena occurring
in response to chronic hepatic injury and encompasses the
epithelial component as well as inflammatory and fibrogenic
changes (6). Ductular reactions are observed in all forms of
CLD with hepatocyte injury and replicative arrest. However,
depending on the underlying aetiology, they display diverse
morphologies, ranging from well-formed ductules to irregular strings of cells without obvious lumina (7). Irrespective
of the injury stimulus, ductular reactions, activated biliary
epithelial cells and LPCs are generally closely associated with
inflammatory cell populations and fibrosis-driving, activated
hepatic stellate cells, forming a very dynamic injury and regeneration niche (Figure 1). Although significant differences
in injury and repair dynamics can be observed in different
forms of CLD (8), epithelial, inflammatory and fibrogenic
cells principally orchestrate liver regeneration versus disease
progression through chemokine and cytokine crosstalk in all
clinical settings (6, 9–13).

Figure 1. The injury and regeneration niche during chronic liver injury. Murine chronic liver injury induced by feeding a
choline-deficient, ethionine-supplemented diet 15 leads to formation of an injury and regeneration niche, involving CKpan+
ductular cells and LPCs (green), αSMA+ hepatic stellate cells (red) and CD45+ inflammatory cells (white). DAPI was used for
nuclear localisation.
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Liver Progenitor Cells and Cancer Stem Cells
LPCs are defined as a heterogeneous pool of immature, bipotential hepatic cells with diverse marker expression profiles
and the ability to differentiate into either hepatocytes or biliary epithelial cells, depending on the underlying injury stimulus and thus tissue requirements. They are undetectable in
healthy liver but upon injury emerge in portal areas near the
Canals of Hering. Their origin and liver repopulation capacity have been controversially discussed (14). Studies using the
choline-deficient, ethionine-supplemented model of chronic
liver injury (15) reported that LPCs expressing osteopontin
(16) or Foxl1 (17) contributed to hepatocellular regeneration.
In addition, transplantation of clonogenic LPCs into hepatocyte-senescent murine livers, induced through deletion of
the E3 ubiquitin ligase Mdm2, resulted in restoration of the
hepatic parenchyma through generation of hepatocytic or
biliary epithelia (18). The exact underlying mechanisms of
LPC-mediated liver regeneration are not always clear; however, hepatocyte senescence seems to be a definite histological
requirement (19).
The degree of LPC proliferation directly correlates with
the severity of hepatocyte replicative arrest and the inflammatory and fibrogenic responses to CLD (20). Targeting
of c-kit+ LPCs through the multikinase inhibitor imatinib
mesylate during experimental chronic liver injury resulted
in reduced fibrogenesis and carcinogenesis (21). Moreover,
the presence of hepatobiliary LPCs, marked by epithelial
cell adhesion molecule (EpCAM) and cytokeratin 7 and 19,
predicted an increased risk of tumour formation in cirrhotic,
hepatitis C virus–infected patients (22). This suggests that
some LPCs either indirectly influence tumour development
by regulating the fibrogenic potential and chemotaxis of
neighbouring hepatic stellate cells (9, 12, 13, 23) or directly as
tumour-initiating or cancer stem cells (CSCs).
In general, CSCs are defined as undifferentiated cells
that are capable to self-renew, initiate and maintain tumour
growth and may be responsible for tumour recurrence after
resection. Haraguchi and colleagues first postulated the existence of liver CSCs, based on the finding that the hepatocellular carcinoma cell lines HuH7 and Hep3B contained
0.9–1.8% of side population cells with the ability to efflux the
fluorescent nucleic acid-binding dye Hoechst 33342 through
high activity of adenosine triphosphate-binding cassette
transporters (24). Similar side population cells successfully
induced xenograft tumours upon transplantation into immunodeficient NOD/SCID mice, while no tumour formation was
observed when non-side population cells were transplanted
(25). Subsequently, numerous studies have focussed on the
identification of reliable marker expression profiles for liver
CSCs. The CD133+ subpopulation of various hepatocellular
carcinoma cell lines displayed a more immature, proliferative
phenotype with greater colony formation capacity in vitro
and upon xenotransplantation a higher tumorigenic potential compared to the CD133− cellular counterpart (26–28).

Within the CD133+ population, cells with the expression profile CD133+CD44+ have been described as more tumorigenic
and metastatic than CD133+CD44− cells (29, 30). Other studies have suggested the mucin-like cell surface glycoprotein
CD24 (31) and the glycosylphosphatidylinositol-anchored
glycoprotein CD90 or Thy-1 (32) as liver CSC markers.
The transmembrane glycoprotein EpCAM is expressed by
normal LPCs and CSCs and regulates cell–cell adhesion,
proliferation, migration, differentiation and invasion (33).
EpCAM is transcriptionally activated by the Wnt/β-catenin
pathway, while inhibition of Wnt/β-catenin signalling was
shown to suppress its expression (34). Interestingly, both
CD44 and CD24 are direct Wnt target genes, marking this
signalling pathway a key player in CSC biology and therefore
a potential therapeutic target to prevent or treat hepatocellular carcinoma.
There is strong experimental evidence for Wnt signalling
directly regulating the biology of LPCs and CSCs. Using the
3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) model of
chronic liver injury, Hu et al. demonstrated Wnt/β-catenin
signalling activity in proliferating A6+ LPCs and ductular
reactions. Primary LPCs showed active, nuclear β-catenin
and entered the cell cycle upon Wnt3a stimulation in vitro
(35). A constitutively active β-catenin mutant was shown
to promote LPC expansion in rodents subjected to the
2-acetylaminofluorene/partial hepatectomy model. In addition, the less differentiated, LPC-like, OV6+ subpopulation
of hepatocellular carcinoma cells displayed endogenously active Wnt/β-catenin signalling, coupled with a more aggressive
phenotype, as judged by greater tumorigenicity and chemoresistance (36). Boulter and colleagues reported Wnt3a-induced
expression of the ubiquitin ligase Numb, which is required to
leave the biliary differentiation path, and hepatocyte nuclear
factor 4α in the LPC line BMOL (37), together inducing its
differentiation towards the hepatocyte lineage (38).

The Wnt/β-Catenin Signalling Pathway
The Wnt signalling pathway is highly conserved and has
been associated with embryogenesis, proliferation, differentiation as well as carcinogenesis (39–41). It consists of
19 Wnt ligands, 10 Wnt receptors, referred to as frizzleds
(FZD), a family of co-receptors, including low-density lipoprotein receptor-related proteins 5 and 6 (LRP5 and 6),
and two branches of the pathway exist (42, 43). The non-
canonical pathway comprises the planar cell polarity
pathway (PCP) and the Ca2+ pathway. These are β-cateninindependent pathways that play roles in the regulation of
the actin cytoskeleton and cytoskeletal rearrangement and
will not be discussed further. In contrast, the canonical
pathway is β-catenin-dependent and of particular interest
therapeutically, as aberrant activation of this pathway has
been postulated as a key driver in many malignancies such
as prostate, colorectal, ovarian and liver cancer (41).

Journal of Renal and Hepatic Disorders 2018; 2(1): 1–9

3

Shirolkar GD et al.

During the inactive ‘off’ state, there is no Wnt ligand
bound to the FZD receptor, which results in the multi-protein
destruction complex, consisting of glycogen synthase kinase
3β (GSK3β), casein kinase 1 (CK1), adenomatous polyposis
coli (APC) and Axin, to bind β-catenin. The destruction complex then phosphorylates β-catenin in a sequential pattern on
residues serine 33 (S33), serine 37 (S37) and threonine (T41).
Beta-catenin is then ubiquitinated by the E3-ligase beta-
transducin repeat containing protein (βTRCP) and marked
for proteasomal degradation, preventing it from translocating
to the nucleus. The transcription repressor Groucho remains
bound to T-cell factor/lymphoid enhancer factor (TCF/LEF)
transcription factors, inhibiting transcription of target genes
such as c-Myc and cyclin D1 (Figure 2) (40). Conversely, in

the active ‘on’ state, a Wnt ligand binds to a FZD receptor,
activating the protein dishevelled (Dvl), a cytoplasmic phosphoprotein crucial for Wnt signal transduction. Axin is recruited to the plasma membrane, binding to the co-receptor
LRP5/6 and inhibiting GSK3β and the destruction complex.
This allows unphosphorylated β-catenin to accumulate in the
cytoplasm and translocate into the nucleus, where Groucho is
displaced and unbound from TCF/LEF transcription factors.
In this case, β-catenin is able to bind and activate downstream
signalling (Figure 2) (40). It has been estimated that Wnt/βcatenin signalling regulates the expression of more than 80
target genes involved in cell fate determination, development,
regeneration, zonation, metabolism, fibrosis and carcinogenesis of the liver (44, 45).

Figure 2. The canonical Wnt/β-catenin pathway. In the absence of a Wnt signal (‘OFF’ state), the destruction complex, consisting of adenomatosis polyposis coli (APC), glycogen synthase kinase 3-β (GSK3β), casein kinase 1 (CK1) and Axin, binds
and phosphorylates β-catenin, marking it for ubiquitination by the E3 ubiquitin ligase subunit beta-transducin repeat containing
protein (βTRCP) and degradation through the proteasome. In this case, the repressor Groucho remains bound to T-cell factor/
lymphoid enhancer factor (TCF/LEF) transcription factors, inhibiting transcription of target genes such as c-Myc and cyclin D1
(A). When a Wnt protein binds a Frizzled receptor and the low-density lipoprotein receptor-related proteins 5 and 6 (LRP5/6) in
the ‘ON’ state, the protein dishevelled (Dvl) activates a cascade, which eventually disrupts the destruction complex, leading to stabilisation, cytoplasmic accumulation and nuclear translocation of β-catenin and ultimately the transcription of target genes (B).
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Wnt/β-Catenin Signalling in Liver Metabolism
The liver regulates metabolic homeostasis by controlling
glycogen storage, gluconeogenesis, plasma protein synthesis, lipoprotein synthesis and detoxification. To manage
fluctuating metabolic demands, hepatic cells constantly
alter the expression of respective regulatory pathways. Accordingly, hepatic Wnt signalling activity is modified under
different physiological and pathophysiological conditions
(45). In adult healthy hepatocytes, β-catenin is ubiquitously
expressed, but it is more active in pericentral compared to
periportal hepatocytes (44). Expression of β-catenin in periportal regions is inhibited by hepatocyte nuclear factor 4α
(46). In contrast, pericentral hepatocytes display basal activation of β-catenin signalling, controlling expression levels
of glutamine synthetase, ornithine aminotransferase and the
glutamate transporter GLT-1, which together regulate glutamine metabolism (47). This heterogeneous distribution of
metabolic function across the lobule reflects hepatic zonation
and is necessary to achieve optimal metabolic regulation.
Benhamouche and colleagues established that the Wnt/βcatenin pathway is a major control switch pathway for metabolic zonation by demonstrating that blocking of β-catenin
in hepatocytes by infection with an adenovirus encoding the
Wnt signalling antagonist Dickkopf-1 (Dkk-1) resulted in expansion of the periportal transcriptome and downregulation
of perivenous genes. Conversely, constitutive activation of
β-catenin through liver-induced disruption of the negative
regulator APC reversed this gene expression profile and induced the perivenous gene expression programme (48).
The localisation and signalling activity of β-catenin becomes modified upon liver injury (Figure 3) (44, 49). Debebe
and colleagues demonstrated recently that hepatic steatosis
experimentally induced by feeding of a high fat diet, deletion
of phosphatase and tensin homologue deleted on chromosome 10 (Pten) or transgenic expression of HCV core/NS5A
protein, all resulted in macrophage-secreted Wnt activating
CD133+CD49f+ tumour-initiating cells. These data strongly
suggested a Wnt/β-catenin-mediated link between obesity
and cancer (50). In addition, β-catenin was shown to regulate hepatic gluconeogenesis during starvation and insulin-
resistant conditions via interaction with the transcription
factor forkhead box protein O 1 (FoxO1). This interaction
leads to a change in expression of genes encoding the enzymes
glucose-6-phosphatase and phosphoenolpyruvate carboxykinase, which then determine the rate of hepatic gluconeogenesis (44, 51). During oxidative stress conditions, β-catenin
interacts with FOXO and enhances FOXO transcriptional
activity to induce expression of targets for detoxification of
reactive oxygen species (52). FOXO factors are sensitive to
increased insulin levels, hence the interaction of β-catenin
and FOXO is particularly important in diseases associated
with insulin resistance, such as non-alcoholic fatty liver
disease (NAFLD), non-alcoholic steatohepatitis (NASH)
and the metabolic syndrome in general (44). The metabolic

syndrome, previously known as the insulin-resistance syndrome, has been defined as a clustering of the risk factors,
namely, central obesity, hypertension, hypertriglyceridaemia,
hyperglycaemia and low levels of high-density lipoprotein
(53). Metabolic syndrome as well as NAFLD are associated
with reduced insulin sensitivity and decreased insulin effects
on glucose and lipid metabolism (54).
Numerous studies have established a role of the Wnt/β-
catenin pathway in the metabolic syndrome since it was
demonstrated that Wnt signalling represents a molecular
switch to control adipogenesis. Activation of the canonical Wnt/β-catenin pathway through Wnt10b, inhibition of
GSK3β or expression of dominant stable β-catenin prevented
differentiation of preadipocytes and myoblasts through inhibition of the adipogenic transcription factors CCAAT/
enhancer-binding protein α (C/EBPα) and peroxisome proliferator-activated receptor γ (PPARγ) (55, 56). Kennell and
MacDougald investigated Xenopus Wnt8 and FZD1 or FZD2
chimeras and established a role for both β-catenin-dependent
and β-catenin-independent mechanisms in mesenchymal cell
fate and adipogenesis (57). Conversely, in a recent report, inhibition of Wnt signalling through the Wnt-inhibitory molecule
sclerostin led to spontaneous adipogenesis of pre-adipocytes
and mesenchymal precursors (58), supporting the concept of
Wnt signalling controlling the adipogenic switch.

Wnt/β-Catenin Signalling and Cancer
In hepatocellular carcinoma cells, the most frequent mutations occur in TP53, coding for the tumour suppressor p53,
and CTNNB1, the β-catenin gene (59). Coste and colleagues
suggested that 26% of human and 50% of mouse hepatocellular carcinomas carry activating mutations in CTNNB1 (60).
Subsequent studies supported these findings and reported up
to 44% of hepatocellular carcinomas with CTNNB1 mutations (61–64). Activation of β-catenin is hypothesised to
be due to mutations in exon-3 at the serine and/or threonine sites near the NH2 terminus in CTNNB1, which inhibit
phosphorylation-dependent degradation of the β-catenin
protein, leading to an aberrant activation of the canonical
Wnt/β-catenin pathway (44). Simultaneous mutation of the
β-catenin gene and the tumour suppressor H-ras or p21 by
an adenovirus-mediated liver-specific Cre-expression system
resulted in 100% tumour incidence with short latency of only
several weeks (65). Interestingly, mutations in the β-catenin
gene in hepatocellular carcinomas induce overexpression
of β-catenin targets such as the glutamine synthetase gene
GLUL (66, 67), whereas hepatocytes from glutamine synthetase-negative tumours are often H-ras or BRAF mutated
and express E-cadherin, reflecting perivenous and periportal
profiles, respectively (68). Loss-of-function in APC and Axin
is mutually exclusive to CTNNB1 mutations and has been detected in 1–3% and 8–15% of hepatocellular carcinoma cases
(for review, see (69)).
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Figure 3. Beta-catenin and CK19 expression in healthy and injured liver. In healthy mouse liver, only ducts stain with an antibody
targeting CK19 and show cytoplasmic and nuclear β-catenin expression, while β-catenin is exclusively membrane-bound in periportal hepatocytes (healthy liver, left panel). In injured liver (2-week treatment with a choline-deficient, ethionine-supplemented
diet15), the CK19+ compartment expands and demonstrates strong cytoplasmic and nuclear β-catenin, signifying active signalling
(injured liver, right panel).

In a 2009 study, the Wnt ligands Wnt3, Wnt9a and Wnt10b
were shown to be highly expressed in most hepatocellular carcinoma cell lines, irrespective of their differentiation
status. Clear profiles were, however, observed with Wnt2b,
Wnt4, Wnt5a, Wnt5b and Wnt7b, which were overexpressed
in poorly differentiated cell lines, while Wnt8b and Wnt9b
were only expressed in well-differentiated cell lines. These
data suggested canonical Wnt signalling activity in well-
differentiated cells, contributing to tumour initiation and its
repression in poorly differentiated cell lines, which the authors
hypothesised to regulate tumour progression (70). Other Wnt

pathway components associated with hepatocellular carcinoma development include Wnt signalling antagonists such
as secreted frizzled-related proteins (SFRPs), Wnt-inhibitory
factor (WIF)-1 and Dickkopf (Dkk) proteins. SFRP1 has
been suggested as a tumour suppressor gene, since its expression was downregulated due to promoter hypermethylation
in 76.1% of hepatocellular carcinoma specimens at the RNA
level and in 30% at the protein level (71). In hepatocellular
carcinoma cell lines and clinical specimens, WIF-1 expression
was equally found to be repressed by promoter hypermethylation, suggesting epigenetic inactivation as the primary cause
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for WIF-1 loss during hepatocarcinogenesis (72). Inactivity
of the negative Wnt regulators Dkk2 and Dkk3 has been reported in human gastrointestinal tumours (73). Fatima and
colleagues observed significantly reduced mRNA expression
of Dkk4 in almost half of all investigated hepatocellular carcinoma cases. Immunohistochemical data linked decreased
Dkk4 expression to accumulation of β-catenin in hepatocellular carcinoma tissue. In addition, the authors showed
that Dkk4 overexpression in hepatocellular carcinoma cell
lines resulted in reduced cell proliferation, colony formation
and cell migration, suggesting a tumour-suppressive role for
Dkk4 (74). A recent study demonstrated that hepatocellular
carcinoma cells proliferate upon stimulation in high glucose
conditions as a result of Dkk4 downregulation, allowing
Wnt3a-mediated β-catenin signalling and c-Myc upregulation (75), suggesting the Wnt pathway may be a therapeutic
target in insulin-resistant conditions, leading to hepatocellular carcinoma.

Conclusion
Many diverse signalling pathways regulate liver development,
homeostasis, regeneration and carcinogenesis. Given the
strong evidence for an association of (i) progressive liver disease and LPCs, (ii) CSC-like LPCs and liver tumour formation and (iii) obesity, insulin resistance, hepatic steatosis and
hepatocarcinogenesis, and the fact that the Wnt/β-catenin
signalling seems to be playing major roles in all these processes, this pathway represents a particularly promising therapeutic target to prevent or treat hepatocellular carcinoma.
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